JP2005516938A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005516938A5 JP2005516938A5 JP2003552781A JP2003552781A JP2005516938A5 JP 2005516938 A5 JP2005516938 A5 JP 2005516938A5 JP 2003552781 A JP2003552781 A JP 2003552781A JP 2003552781 A JP2003552781 A JP 2003552781A JP 2005516938 A5 JP2005516938 A5 JP 2005516938A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- compound
- cancer
- animal
- monosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 150000001875 compounds Chemical group 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 241001465754 Metazoa Species 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 6
- -1 hydroxy, carboxy Chemical group 0.000 claims 6
- 150000002772 monosaccharides Chemical class 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 4
- 150000002016 disaccharides Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940088597 hormone Drugs 0.000 claims 4
- 239000005556 hormone Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 238000000315 cryotherapy Methods 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 238000001415 gene therapy Methods 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 239000002244 precipitate Substances 0.000 claims 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 229960000583 acetic acid Drugs 0.000 claims 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000012362 glacial acetic acid Substances 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 230000003054 hormonal effect Effects 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 239000000376 reactant Substances 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 150000003456 sulfonamides Chemical group 0.000 claims 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- BZMHXOOEJJRVGM-UHFFFAOYSA-N 1,2-bis(1-methyl-2,3-dihydroindol-2-yl)ethane-1,2-dione Chemical compound C1C2=CC=CC=C2N(C)C1C(=O)C(=O)C1N(C)C2=CC=CC=C2C1 BZMHXOOEJJRVGM-UHFFFAOYSA-N 0.000 claims 1
- JHFAEUICJHBVHB-UHFFFAOYSA-N 1h-indol-2-ol Chemical compound C1=CC=C2NC(O)=CC2=C1 JHFAEUICJHBVHB-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001308 synthesis method Methods 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/021,589 US6566341B1 (en) | 2001-12-13 | 2001-12-13 | Derivative of isoindigo, indigo and indirubin for the treatment of cancer |
| US40726702P | 2002-09-03 | 2002-09-03 | |
| PCT/US2002/039866 WO2003051900A1 (en) | 2001-12-13 | 2002-12-13 | Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005516938A JP2005516938A (ja) | 2005-06-09 |
| JP2005516938A5 true JP2005516938A5 (enExample) | 2005-12-22 |
Family
ID=26694875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003552781A Pending JP2005516938A (ja) | 2001-12-13 | 2002-12-13 | イソインジゴ、インジゴおよびインジルビンの誘導体、ならびに癌治療における使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6933315B2 (enExample) |
| EP (1) | EP1458734B1 (enExample) |
| JP (1) | JP2005516938A (enExample) |
| AT (1) | ATE484514T1 (enExample) |
| AU (1) | AU2002357191A1 (enExample) |
| CA (1) | CA2469649C (enExample) |
| DE (1) | DE60237993D1 (enExample) |
| WO (1) | WO2003051900A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| US20100098702A1 (en) * | 2008-09-16 | 2010-04-22 | Longgui Wang | Method of treating androgen independent prostate cancer |
| US7582670B2 (en) | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
| US8748475B2 (en) | 2004-01-12 | 2014-06-10 | Natrogen Therapeutics International, Inc. | Methods and compositions for treating lupus |
| US8563525B2 (en) | 2004-01-12 | 2013-10-22 | Natrogen Therapeutics International, Inc. | Methods of treating an inflammatory-related disease |
| CN101074229B (zh) * | 2007-06-08 | 2010-09-01 | 无锡杰西医药科技有限公司 | 7-氮杂靛玉红和7-氮杂异靛蓝衍生物制备及其药学用途 |
| CN101426268B (zh) * | 2007-11-02 | 2010-08-25 | 大唐移动通信设备有限公司 | 导频资源分配方法、系统和设备 |
| US8563595B2 (en) * | 2008-11-14 | 2013-10-22 | Board Of Regents, The University Of Texas System | Treatment of cancer with complex organic-inorganic pigment compositions |
| WO2013142817A2 (en) * | 2012-03-23 | 2013-09-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| EP3597178A1 (en) * | 2012-06-21 | 2020-01-22 | Phosphorex Inc. | Nanoparticles of indirubin, derivatives thereof and methods of making and using same |
| CN103333161B (zh) * | 2013-05-28 | 2015-09-30 | 滁州市洛达生物科技有限公司 | 1’-氧代靛玉红的制备和用途 |
| WO2018216795A1 (ja) * | 2017-05-26 | 2018-11-29 | 大鵬薬品工業株式会社 | 新規なビフェニル化合物を用いた抗腫瘍効果増強剤 |
| MX391414B (es) | 2017-05-26 | 2025-03-21 | Taiho Pharmaceutical Co Ltd | Compuesto novedoso de bifenilo o sal del mismo. |
| US12435128B2 (en) | 2017-05-31 | 2025-10-07 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| WO2020117487A1 (en) * | 2018-12-07 | 2020-06-11 | Natrogen Therapeutics International, Inc. | Polymorphic form of meisoindigo and modified formulation of meisoindigo |
| PH12022551169A1 (en) | 2019-11-13 | 2024-02-19 | Astex Pharmaceuticals Inc | METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS |
| US11345818B1 (en) | 2020-12-29 | 2022-05-31 | Industrial Technology Research Institute | Dye for fiber and dyeing method |
| US20240285660A1 (en) * | 2021-04-27 | 2024-08-29 | Curapep Llc | Composition for wound relief and inhibiting a phd protein and methods of treatment |
| CN114920728B (zh) * | 2022-05-27 | 2023-10-20 | 中南大学 | 一种甲异靛衍生物及其制备方法与应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS617254A (ja) * | 1984-06-20 | 1986-01-13 | Isukura Sangyo Kk | ビスインドリノンおよびそれを主成分とする制癌剤 |
| US5696092A (en) * | 1995-03-07 | 1997-12-09 | George Washington University | Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers |
| DE69905712T2 (de) * | 1998-05-29 | 2004-01-29 | Gerhard Eisenbrand | Verwendung von indigoähnlichen bisindolen zur herstellung eines arzneimittels zur hemmung cyclin abhängiger kinasen |
| CA2369626C (en) * | 1999-04-12 | 2009-01-13 | Gerhard Eisenbrand | Use of cell membrane penetrating indigoid bisindole derivatives |
| HUP0200724A3 (en) * | 1999-04-12 | 2002-10-28 | Eisenbrand Gerhard | Indigoid bisindole derivatives and pharmaceurical compositions containing them |
-
2002
- 2002-12-13 JP JP2003552781A patent/JP2005516938A/ja active Pending
- 2002-12-13 AU AU2002357191A patent/AU2002357191A1/en not_active Abandoned
- 2002-12-13 EP EP02805123A patent/EP1458734B1/en not_active Expired - Lifetime
- 2002-12-13 WO PCT/US2002/039866 patent/WO2003051900A1/en not_active Ceased
- 2002-12-13 AT AT02805123T patent/ATE484514T1/de not_active IP Right Cessation
- 2002-12-13 CA CA2469649A patent/CA2469649C/en not_active Expired - Lifetime
- 2002-12-13 DE DE60237993T patent/DE60237993D1/de not_active Expired - Lifetime
-
2004
- 2004-06-10 US US10/864,458 patent/US6933315B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005516938A5 (enExample) | ||
| CA2469649A1 (en) | Derivatives of isoindigo, indigo and indirubin and use in treating cancer | |
| EP2393827B1 (en) | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens | |
| EP2268604B1 (en) | Therapies for cancer using isotopically substituted lysine | |
| HUT59370A (en) | Chelating agents for complex formation with radioactive isotopes, their metal complexes and the use thereof for diagnostic and therapeutic purposes | |
| US9125946B2 (en) | Halogenated phenols for diagnostics, antioxidant protection and drug delivery | |
| HK1221712A1 (zh) | 雄激素受体调节剂的酯衍生物及其使用方法 | |
| US20130336962A1 (en) | Aziridine bisphenol ethers and related compounds and methods for their use | |
| WO2016141458A1 (en) | Bisphenol ether derivatives and methods for using the same | |
| WO2018045450A1 (en) | Bisphenol a compounds and methods for treating drug-resistant androgen receptor mediated cancers | |
| CN1183097A (zh) | 放射致敏二胺及其药物组合物 | |
| NZ726348A (en) | Androgen receptor modulators and methods for their use | |
| TW593328B (en) | Proactive antitumor compounds | |
| CN114349807B (zh) | 一种唾液酸连接吲哚菁绿Sia-ICG及其制备方法和应用 | |
| TW202444713A (zh) | 靶向成纖維細胞活化蛋白的配體 | |
| CN1122132A (zh) | 配位体及其金属配合物 | |
| CN114702544B (zh) | 一种氨基甾体化合物及其制备方法和应用 | |
| CN104974252B (zh) | 一种抑制肿瘤生长的抗体-小分子药物偶联物及其制备方法和用途 | |
| CN112194673A (zh) | 一种联合抗肿瘤化合物及其制备方法和应用 | |
| JPS5874641A (ja) | デカルボキシラ−ゼを阻害するフツ素化アルカンジアミン誘導体 | |
| CN101289421A (zh) | 烟酰氨基酸类化合物的合成方法及其对肿瘤放疗的增敏作用 | |
| CN117986320A (zh) | 一种靶向降解细胞内bcl-3的protac化合物及其制备方法与应用 | |
| US10220100B2 (en) | Halogenated phenols for diagnostics, antioxidant protection and drug delivery | |
| JP3718533B2 (ja) | ジヒドロキシフェニルスルフィド誘導体またはその塩を含む抗メラノーマ剤 | |
| WO2019034147A1 (zh) | 1-甲基-色氨酸类化合物及其制备方法和用途 |